The collaboration aims to identify preclinical assets against novel targets representing first-in-class opportunities, while Alacrita will support Debiopharm in search for small molecules, antibody or peptide-based product candidates.
Debiopharm business development and licensing vice president David Deperthes said, "As such, the area represents a strategic priority for us as we source opportunities from around the world to expand our pipeline of novel medicines."
Alacrita is responsible to identify opportunities for Debiopharm, that focuses on prescription drug development, away on the East Coast.
Alacrita consulting partner Rob Johnson said, "Debiopharm’s resources and expertise in global pharmaceutical development make it an ideal partner for Massachusetts organizations looking to move their preclinical programs into clinical trials."